Background

Scientists have learned that a build-up of amyloid plaque in the brain is neurotoxic (which means it is bad for brain cells) and can cause brain cells to degenerate and die leading a loss of brain cells and subsequent memory loss. We are conducting a study to see if a study medication which is designed to remove amyloid plaque from the brain alone or in combination with a study medication which blocks the production of amyloid products can effectively remove amyloid plaque in the brain and whether it can either stop or slow down the loss of memory.

Criteria to participate

Some of the criteria patients must satisfy to participate are:

  • Be between 60 and 85 years old
  • Have a study partner (i.e. someone who is with you 10 hours or more each week and would be willing to come to the center at selected visits or speak with investigators on eh phone)
  • Demonstrate a mild level of memory loss when tested
  • Have a positive PET (brain scan) for amyloid plaque
  • Have a positive PET scan for tau protein
  • Can have an MRI (that is, no metal in your head or upper torso and not claustrophobic)
  • Has no medical conditions which may also cause memory loss

About the Study

Once the study criteria are met, the patient will receive either the study medication which is designed to remove amyloid plaque alone, or in combination with an inhibitor of amyloid protein production or a placebo for the duration of the study; neither the patient nor the doctor will know which is assigned. The patient will have study medication or placebo infused into an arm vein every 4 weeks and will take a pill to take daily for the 76 week duration of the study. During the study, MRI scans of the brain and amyloid and tau PET scans will be obtained. There is no cost to the patient for study-related medical care or for any of the scans, memory testing, or medication required in the study.

Current Studies

We are currently conducting the following study with 2 medications, one which seeks to remove brain amyloid plaque and one which blocks production of amyloid products.

Study

Sponsor

Study medications

NCT number

Study Status

AACG

Lilly

LY3002813, LY3202626

NCT03367403

Scheduled to begin in April, 2018

You may use the NCT number to learn more about the study we are conducting by going to clinicaltrials.gov and entering the number in the search bar.